Ascletis Pharma Inc. appointed Handan He, a former Novartis AG executive, as the company's chief scientific officer.
The new chief scientific officer will report to Ascletis Pharma Chairman and CEO Jinzi Wu. She was the global head of computational, biopharmaceutics and translational pharmacokinetics/pharmacodynamics at Novartis.
Over her 22-year tenure at Novartis, He authored more than 30 clinical trial applications and three new drug marketing applications.
Ascletis former chief medical officer Li Zhengqing left the company in July after joining less than six months ago. Former CFO Lindi Tan also departed the company on Sept. 30, after joining less than one year ago.
